Advertisement
Singapore markets closed

  • Straits Times Index

    3,314.14
    +8.12 (+0.25%)
     

  • S&P 500

    5,462.47
    -2.15 (-0.04%)
     

  • Dow

    39,256.21
    +105.88 (+0.27%)
     

  • Nasdaq

    17,637.19
    -52.18 (-0.29%)
     

  • Bitcoin USD

    61,380.98
    -2,900.18 (-4.51%)
     

  • CMC Crypto 200

    1,260.66
    -49.06 (-3.75%)
     

  • FTSE 100

    8,272.09
    +34.37 (+0.42%)
     

  • Gold

    2,344.90
    +13.70 (+0.59%)
     

  • Crude Oil

    80.66
    -0.07 (-0.09%)
     

  • 10-Yr Bond

    4.2540
    -0.0030 (-0.07%)
     

  • Nikkei

    38,804.65
    +208.18 (+0.54%)
     

  • Hang Seng

    18,027.71
    -0.81 (-0.00%)
     

  • FTSE Bursa Malaysia

    1,589.66
    -0.71 (-0.04%)
     

  • Jakarta Composite Index

    6,889.17
    +9.19 (+0.13%)
     

  • PSE Index

    6,272.46
    +113.98 (+1.85%)
     

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

Business Wire
·1-min read

GERMANTOWN, Md., June 13, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Breakfast and refreshments will be provided beginning at 9:15 am ET on Sunday, June 23, 2024, in advance of a business update presentation from management scheduled to begin, at 10:00 am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at hannah@gilmartinir.com by June 21, 2024, to register.

ADVERTISEMENT

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613143680/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com